Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 800-984-9 | CAS number: 1428547-35-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.66 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 18
- Dose descriptor starting point:
- NOAEL
- Value:
- 3.25 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 11.79 mg/m³
- Explanation for the modification of the dose descriptor starting point:
- Starting point is the NOAEL for the registered substance (see discussion) which is based upon cross-reading from the 28-day study on (Z)-octadec-9 –enylamine resulting to a NOAEL of 3.25 mg/kg bw/day. This is then converted to the corresponding value of the salt, resulting to a NOAEL of about 6.7 mg/kg bw/day: Mw oleylamine = 267.5, MW salt = 547.5 ; 3.25 x 547.5/267.5 = 6.7 mg/kg bw/day From this follows for the corrected 8 hr inhalation NOAEC for workers (6.7 mg/kg) * 1.76 mg/m3 = 11.79 mg/m3. No factor 2 for route extrapolation from oral to inhalationis applied. Due to very low vp (<< 0.0075 Pa as this is based on the available data on oleylamine), significant exposure is only possible as aerosol. If any inhalation does occur, this can only be in the form of larger droplets, as the use does not include fine spraying. Droplets will deposit mainly on upper airways, and will be subsequently swallowed following mucociliary transportation to pharynx. This results to no principal difference in absorption compared oral route.
- AF for dose response relationship:
- 1
- Justification:
- No specific concerns; starting point is NOAEL, effects at LOAEL are not severe and of local nature.
- AF for differences in duration of exposure:
- 6
- Justification:
- Default assessment factor for subacute to chronic.
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- Already included in NOAEC calculation
- AF for other interspecies differences:
- 1
- Justification:
- ECETOC reported in 2010 after an extensive review that there is no justification for the suggested additional factor of 2.5 for this, therefore a factor of 1 has been applied. As effects are interpreted as being local and related to the route of exposure (see comments), the already applied allometric scaling already represents a worst case.
- AF for intraspecies differences:
- 3
- Justification:
- ECETOC reported in 2010 after an extensive scientific review that the appropriate fact for intra-species differences for workers is 3 and not 5. As the effects for which the risk assessment is made is based on a local response following an non-specific mechanism with expected inherently relative low variation between individuals, no additional factor is needed to accommodate for possible high uncertainty between individuals on the basis of possible specific sensitivities.
- AF for the quality of the whole database:
- 1
- Justification:
- Available data derived from valid studies showing consistent results within category.
- AF for remaining uncertainties:
- 1
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.15 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 72
- Dose descriptor starting point:
- NOAEL
- Value:
- 3.25 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 11.16 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- Starting point is the NOAEL for the registered substance (see discussion) which is based upon cross-reading from the 28-day study on (Z)-octadec-9 –enylamine resulting to a NOAEL of 3.25 mg/kg bw/day. This is then converted to the corresponding value of the salt, resulting to a NOAEL of about 6.7 mg/kg bw/day: Mw oleylamine = 267.5, MW salt = 547.5 ; 3.25 x 547.5/267.5 = 6.7 mg/kg bw/day. A dermal rate has been established to be 60 % dermal absorption may be taken as a worst case for assessment purposes (value taken from the existing EU risk assessment on primary alkylamines) leading to a NOAEL dermal of 11.16 mg/kg bw/day.
- AF for dose response relationship:
- 1
- Justification:
- No specific concerns; starting point is NOAEL, effects at LOAEL are not severe and of local nature.
- AF for differences in duration of exposure:
- 6
- Justification:
- Default assessment factor for subacute to chronic.
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- Default factor for allometric scaling from rat to human.
- AF for other interspecies differences:
- 1
- Justification:
- ECETOC reported in 2010 after an extensive review that there is no justification for the suggested additional factor of 2.5 for this, therefore a factor of 1 has been applied. As effects are interpreted as being local related to the route of exposure, the applied allometric scaling already represents a worst case
- AF for intraspecies differences:
- 3
- Justification:
- ECETOC reported in 2010 after an extensive scientific review that the appropriate fact for intra-species differences for workers is 3 and not 5. As the effects for which the risk assessment is made is based on a local response following an non-specific mechanism with expected inherently relative low variation between individuals, no additional factor is needed to accommodate for possible high uncertainty between individuals on the basis of possible specific sensitivities.
- AF for the quality of the whole database:
- 1
- Justification:
- Available data derived from valid studies showing consistent results within category.
- AF for remaining uncertainties:
- 1
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
Additional information - workers
The registered substance is a salt composed of primary hydrogenated alkylamine and N-hydrogenated tallow fatty acid. As the primary alkyl amine part is much more toxic than the tallow fatty acid part, it is expected that the toxicological behaviour of the substance will not be far different from that of the primary alkylamine compounds or at least not more severe. This has been demonstrated by results obtained with the registered substance in a short-term repeated toxicity study (e.g. 14 days). Thus, assessment of the registered substance can be integrated in thecurrent approach of grouping of primary alkylamines substances. Regarding the toxicity of these latter, it has been expected that the members with a shorter chain and/or a higher degree of insaturation will have a higher toxicity among the category or at least will represent the worst case. Thus, a read-across could be applied to longer chains into shorter and to saturated molecules into unsaturated ones.
Starting point is the NOAEL for the registered substance which is based upon cross-reading from the 28-day study on (Z)-octadec-9 –enylamine resulting to a NOAEL of 3.25 mg/kg bw/day. This is then converted to the corresponding value of the salt, resulting to a NOAEL of about 6.7 mg/kg bw/day: Mw oleylamine = 267.5, MW salt = 547.5 ; 3.25 x 547.5/267.5 = 6.7 mg/kg bw/day From this follows for the corrected 8 hr inhalation NOAEC for workers (6.7 mg/kg) * 1.76 mg/m3 = 11.79 mg/m3.
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.14 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 42
- Dose descriptor starting point:
- NOAEL
- Value:
- 3.25 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 5.83 mg/m³
- Explanation for the modification of the dose descriptor starting point:
- Starting point is the NOAEL for the registered substance (see discussion) which is based upon cross-reading from the 28-day study on (Z)-octadec-9 –enylamine resulting to a NOAEL of 3.25 mg/kg bw/day. This is then converted to the corresponding value of the salt, resulting to a NOAEL of about 6.7 mg/kg bw/day: Mw oleylamine = 267.5, MW salt = 547.5 ; 3.25 x 547.5/267.5 = 6.7 mg/kg bw/day From this follows for the corrected 8 hr inhalation NOAEC for workers (6.7 mg/kg) * 1/1.15 mg/m3 = 5.83 mg/m3. No factor 2 for route extrapolation from oral to inhalationis applied. Due to very low vp (<< 0.0075 Pa as this is based on the available data on oleylamine), significant exposure is only possible as aerosol. If any inhalation does occur, this can only be in the form of larger droplets, as the use does not include fine spraying. Droplets will deposit mainly on upper airways, and will be subsequently swallowed following mucociliary transportation to pharynx. This results to no principal difference in absorption compared oral route.
- AF for dose response relationship:
- 1
- Justification:
- No specific concerns; starting point is NOAEL, effects at LOAEL are not severe and of local nature.
- AF for differences in duration of exposure:
- 6
- Justification:
- Default assessment factor for subacute to chronic.
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- Already included in NOAEC
- AF for other interspecies differences:
- 1
- Justification:
- ECETOC reported in 2010 after an extensive review that there is no justification for the suggested additional factor of 2.5 for this, therefore a factor of 1 has been applied. As effects are interpreted as being local and related to the route of exposure (see comments), the already applied allometric scaling already represents a worst case.
- AF for intraspecies differences:
- 7
- Justification:
- ECETOC reported in 2010 after an extensive scientific review that the appropriate fact for intraspecies differences for general public is 5 and not 10, In this case the factor 7 is used to accommodate for the possible high uncertainty between individuals as the effects for which the risk assessment is made possibly includes a local response.
- AF for the quality of the whole database:
- 1
- Justification:
- Available data derived from valid studies showing consistent results within category.
- AF for remaining uncertainties:
- 1
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.07 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 168
- Dose descriptor starting point:
- NOAEL
- Value:
- 3.25 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 11.16 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- Starting point is the NOAEL for the registered substance (see discussion) which is based upon cross-reading from the 28-day study on (Z)-octadec-9 –enylamine resulting to a NOAEL of 3.25 mg/kg bw/day. This is then converted to the corresponding value of the salt, resulting to a NOAEL of about 6.7 mg/kg bw/day: Mw oleylamine = 267.5, MW salt = 547.5 ; 3.25 x 547.5/267.5 = 6.7 mg/kg bw/day. A dermal rate has been established to be 60 % dermal absorption may be taken as a worst case for assessment purposes (value taken from the existing EU risk assessment on primary alkylamines) leading to a NOAEL dermal of 11.16 mg/kg bw/day.
- AF for dose response relationship:
- 1
- Justification:
- No specific concerns; starting point is NOAEL, effects at LOAEL are not severe and of local nature.
- AF for differences in duration of exposure:
- 6
- Justification:
- Default assessment factor for subacute to chronic.
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- Default factor for allometric scaling from rat to human.
- AF for other interspecies differences:
- 1
- Justification:
- ECETOC reported in 2010 after an extensive review that there is no justification for the suggested additional factor of 2.5 for this, therefore a factor of 1 has been applied. As effects are interpreted as being local related to the route of exposure, the applied allometric scaling already represents a worst case
- AF for intraspecies differences:
- 7
- Justification:
- ECETOC reported in 2010 after an extensive scientific review that the appropriate fact for intra-species differences for workers is 3 and not 5. As the effects for which the risk assessment is made is based on a local response following an non-specific mechanism with expected inherently relative low variation between individuals, no additional factor is needed to accommodate for possible high uncertainty between individuals on the basis of possible specific sensitivities.
- AF for the quality of the whole database:
- 1
- Justification:
- Available data derived from valid studies showing consistent results within category.
- AF for remaining uncertainties:
- 1
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 0.04 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 168
- Dose descriptor starting point:
- NOAEL
- Value:
- 3.25 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 6.7 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- Starting point is the NOAEL for the registered substance (see discussion) which is based upon cross-reading from the 28-day study on (Z)-octadec-9 –enylamine resulting to a NOAEL of 3.25 mg/kg bw/day. This is then converted to the corresponding value of the salt, resulting to a NOAEL of about 6.7 mg/kg bw/day: Mw oleylamine = 267.5, MW salt = 547.5 ; 3.25 x 547.5/267.5 = 6.7 mg/kg bw/day.
- AF for dose response relationship:
- 1
- Justification:
- No specific concerns; starting point is NOAEL, effects at LOAEL are not severe and of local nature.
- AF for differences in duration of exposure:
- 6
- Justification:
- Default assessment factor for subacute to chronic.
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- Default factor for allometric scaling from rat to human.
- AF for other interspecies differences:
- 1
- Justification:
- ECETOC reported in 2010 after an extensive review that there is no justification for the suggested additional factor of 2.5 for this, therefore a factor of 1 has been applied. As effects are interpreted as being local related to the route of exposure, the applied allometric scaling already represents a worst case.
- AF for intraspecies differences:
- 7
- Justification:
- ECETOC reported in 2010 after an extensive scientific review that the appropriate fact for intraspecies differences for general public is 5 and not 10, In this case the factor 7 is used to accommodate for the possible high uncertainty between individuals as the effects for which the risk assessment is made possibly includes a local response.
- AF for the quality of the whole database:
- 1
- Justification:
- Available data derived from valid studies showing consistent results within category.
- AF for remaining uncertainties:
- 1
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
Additional information - General Population
No exposure of the general population to the registered substance based on the uses indicated in this dossier that are limited to industrial manufacture and formulation.
However, to allow for evaluation from indirect exposures via the environment, DNELs have been derived for systemic toxicity from long term exposures via all routes.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.